HLS Therapeutics Inc. (HLS.TO)
- Previous Close
4.7500 - Open
4.7500 - Bid 4.2300 x --
- Ask 4.7000 x --
- Day's Range
4.7400 - 4.7500 - 52 Week Range
3.3400 - 7.1200 - Volume
3,900 - Avg. Volume
9,846 - Market Cap (intraday)
151.459M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1600 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield 0.20 (4.21%)
- Ex-Dividend Date Apr 27, 2023
- 1y Target Est
6.70
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
www.hlstherapeutics.com91
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HLS.TO
Performance Overview: HLS.TO
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLS.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLS.TO
Valuation Measures
Market Cap
151.46M
Enterprise Value
241.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.77
Price/Book (mrq)
1.13
Enterprise Value/Revenue
3.82
Enterprise Value/EBITDA
18.72
Financial Highlights
Profitability and Income Statement
Profit Margin
-43.65%
Return on Assets (ttm)
-2.87%
Return on Equity (ttm)
-24.69%
Revenue (ttm)
63.07M
Net Income Avi to Common (ttm)
-27.53M
Diluted EPS (ttm)
-1.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
21.95M
Total Debt/Equity (mrq)
89.69%
Levered Free Cash Flow (ttm)
24.71M
Research Analysis: HLS.TO
Company Insights: HLS.TO
HLS.TO does not have Company Insights